Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The association between polypharmacy and cognitive ability in older adults: A national cohort study
Stockholm University, Faculty of Social Sciences, Aging Research Center (ARC), (together with KI). Stockholm University, Faculty of Social Sciences, Department of Psychology, Stress Research Institute. The University of Sydney, Australia; Monash University, Australia .ORCID iD: 0000-0003-2922-8837
Number of Authors: 22022 (English)In: Research in Social and Administrative Pharmacy, ISSN 1551-7411, E-ISSN 1934-8150, Vol. 18, no 3, p. 2505-2509Article in journal (Refereed) Published
Abstract [en]

Background: Polypharmacy, the use of multiple medications by one individual, may be associated with adverse health outcomes including poor cognition. However, it remains unclear whether a longitudinal relationship exists.

Objectives: To investigate the association between polypharmacy and 3-year cognitive ability in older adults.

Methods: A longitudinal cohort study of older adults 65 years and older, residing in the community, who participated in waves 12 (2012), 13 (2013) and 16 (2016) of the Household Income and Labour Dynamics (HILDA) Survey was conducted. Polypharmacy was defined as the regular use of 5 or more prescription medications. Cognitive ability was assessed using backwards digit span test (BDS), 25-item version of the National Adult Reading Test (NART-25) and symbol-digit modalities test (SDM). Linear regression was used to test the longitudinal association between polypharmacy and cognitive test scores at 3 years. All analyses were adjusted for age, sex, education, comorbidities, socioeconomic and lifestyle factors, and baseline cognitive test scores.

Results: A total of 2141 participants (mean age 72.9 years, 54.4% female) were included in the study sample. Polypharmacy was present in 27.3%. After adjusting for potential confounders, polypharmacy was negatively associated with cognitive ability at 3 years: BDS: −0.067 (95% CI = −0.353 to −0.051), NART-25: −0.071 (95% CI = −1.428 to −0.294), SDM: −0.073 (95% CI = −2.960 to −0.696).

Conclusion: Polypharmacy was associated with poorer cognitive ability at 3 years, even after adjusting for comorbidities and other confounders. Future research should consider the long-term impact of polypharmacy on cognitive ability, and identify strategies to optimise medication use and cognition in older adults.

Place, publisher, year, edition, pages
2022. Vol. 18, no 3, p. 2505-2509
Keywords [en]
polypharmacy, cognition, aged, longitudinal studies, HILDA
National Category
Gerontology, specialising in Medical and Health Sciences Neurosciences
Research subject
Psychology
Identifiers
URN: urn:nbn:se:su:diva-202734DOI: 10.1016/j.sapharm.2021.04.018ISI: 000751828900016OAI: oai:DiVA.org:su-202734DiVA, id: diva2:1644256
Available from: 2022-03-14 Created: 2022-03-14 Last updated: 2023-01-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

Tan, Edwin C. K.

Search in DiVA

By author/editor
Tan, Edwin C. K.
By organisation
Aging Research Center (ARC), (together with KI)Stress Research Institute
In the same journal
Research in Social and Administrative Pharmacy
Gerontology, specialising in Medical and Health SciencesNeurosciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 608 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf